生命科学资讯

Lilly, Innovent pen $8.8B oncology, immunology collab that 'moves beyond traditional licensing'

Small and mighty: single-domain antibodies pack a biological punch

Navigating the complexities of Cell and Gene Therapy supply chains

This Week in Chancery Court: Trump Media SPAC Appeal, Illumina - Bloomberg Law News

Lilly returns to Innovent to partner on cancer and immune diseases

10x Genomics gets injunction against Parse Biosciences' ATAC Products - MSN

CSL signs on to $328M research collab with option for Memo’s immunoglobulin antibody tech

How AI Is reshaping clinical trials and market access

The Data Multiplier Effect: When Expertise, Monitoring, Systems, and AI Align

Mouse skeletal muscle satellite cells co-opt the tenogenic gene Scleraxis to instruct regeneration

Redefining borders in the sensorimotor cortex

Illumina Crash 10% on Earnings: Why the Stock Could Rebound to $185 in 2026 - TIKR.com

10x Genomics Expands Flex Lineup with High-Throughput Single-Cell Assay Launch - MSN

Is 10x Genomics (TXG) Using PharosAI’s NHS Partnership To Quietly Recast Its Spatial Biology Moat? - simplywall.st

Is Illumina’s (ILMN) Clinical Consumables Surge Quietly Redefining Its Core Investment Story? - Yahoo Finance UK

Assessing Illumina (ILMN) Valuation After Recent Share Price Weakness And Mixed Long Term Returns - simplywall.st

Lonza’s Strategic Pivot Fuels Robust Growth and Shareholder Returns - AD HOC NEWS

Hims cancels plans to sell compounded GLP-1 pill after FDA backlash

Hims says it will stop selling GLP-1 pill, after legal pressure from US

#ACTRIMS26: Sanofi unpacks data from a failed Phase 3 tolebrutinib trial in PPMS